IRABGLU® 370 MBq/ml solution for injection, 1 vial containing 10 ml
AEMPS REGISTRATION No.: 82947 – NATIONAL CODE: 721012 For injection
Fludeoxyglucose (FDG) is the most widely-used radiopharmaceutical in molecular imaging diagnosis, more specifically in PET, being used in more than 90% of all explorations. Its clinical indications of use range from oncology, cardiology and neurology to infectious diseases and inflammatory disorders.
In oncological diagnoses, FDG PET is used to visualize the increase in glucose uptake in organs and tissues. Cancer cells consume more glucose than healthy cells, and it is thereby possible to identify diseased zones. Some of the most common indications are for the detection of tumours of unknown origin, liver or bone metastases, lung cancer, breast cancer, head and neck cancer, colorectal cancer, lymphomas, etc.
In cardiology, FDG PET is used to visualize viable myocardium tissue that takes up glucose but is hypoperfused. When conventional imaging techniques prove inconclusive, FDG PET permits the evaluation of myocardial viability in patients with severe ventricular failure who are candidates for revascularization.
In Neurology, FDG PET is used to study interictal glucose hypometabolism, which is of interest in different diseases such as epilepsy. In the diagnosis of infectious or inflammatory disorders, the objective is to identify tissues or structures with an anomalous presence of activated leukocytes.